Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pascal pushes AZ to push Brilinta in diabetes

This article was originally published in Scrip

Executive Summary

AstraZeneca's re-announcement on 5 December that it will open two new large trials of its commercially less-than-brilliant antiplatelet drug Brilinta (ticagrelor) is further evidence that the company is responding to stinging public criticism from its still untarnished CEO Pascal Soriot. In the company's latest attempt to put the drug back on commercial track, Brilinta (Brilique or Possia outside the US) will be tested in two sets of high cardiovascular risk patients representing hundreds of millions of patients worldwide – type 2 diabetics, on the one hand, and those who have suffered non-fatal ischemic disease on the other. In the diabetes trial, the fact that ticagrelor will go head-to-head with aspirin suggests that AstraZeneca may be willing to be aggressive in combatting the aspirin contraindication that Brilinta/Brilique currently carries.

You may also be interested in...



Gender Diversity In Pharma: Caught Between Desire And Reality

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Women In High Places: Slow Progress In Pharma

With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.

Stock Scan April 2018: Pharma's Fizz Falls Flat

In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC023729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel